Skip to content

Application and efficacy evaluation of laparoscopic uterine artery blockage in difficult myomectomy

Application and efficacy evaluation of laparoscopic uterine artery blockage in difficult myomectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063860
Enrollment
Unknown
Registered
2022-09-19
Start date
2022-09-19
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myoma

Interventions

experimental group:uterine artery blockage
comparative group:without uterine artery blockage

Sponsors

Obstetrics and Gynecology Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Women age over 18 years old before premenopausal; 2. Ultrasonography showed uterine leiomyoma; 3. Anemia (hemoglobin concentration < 110g / L), severe dysmenorrhea, or related compression symptoms caused by uterine leiomyoma 4. Planned operation; 5. Ultrasound examination to evaluate the size of the uterus: one of the three diameter lines of long diameter, anteroposterior diameter and left-right diameter is = 8cm; Single myoma = 8cm, or multiple myomas (= 3, total maximum diameter = 8cm) 6. Complete blood routine examination before operation.

Exclusion criteria

Exclusion criteria: 1. Patients requiring total hysterectomy; 2. Pregnant or lactating, or having a pregnancy plan in a short time; 3. Receiving sex hormone related treatment within one month, such as oral contraceptives, estrogen, progesterone, estrogen receptor modulator, progesterone receptor modulator; 4. History of blood transfusion in the past 8 weeks; 5. Suffering from hemoglobin variant diseases, such as sickle cell anemia and thalassemia; 6. Suffering from coagulation disorders; 7. Suffering from other diseases that lead to chronic blood loss, such as peptic ulcer or hemorrhoids; 8. Patient who is participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
blood loss;

Secondary

MeasureTime frame
changes of Hb;peri-operative complication rate;

Countries

China

Contacts

Public ContactYunxi Zheng
yxi_zheng@126.com15921251037

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026